Discover 38 paid clinical trials in Wyoming. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
Wyoming provides a wide range of opportunities for both healthy volunteers and those with specific health needs to participate in paid research studies. Active recruitment is underway in major cities like Cheyenne, Casper, and Laramie, granting access to innovative treatments and high-quality medical support.
Filter
1
Filter results
Results: 38
Active & Responsive
Prevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous Disease
for
Chronic Granulomatous Disease (CGD)
Location: Cheyenne WY, Denver CO, Salt Lake City UT, Helena MT,
Sponsor: Ensoma
Sex: All
Age: 0+
Code: NCT06605378
Recruiting
New
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
Molecular Genetics Studies of Cancer Patients and Their Relatives
for
Malignant Neoplasm
Location: Cheyenne WY, Albuquerque NM, Post Falls ID, Amarillo TX,
Sponsor: City of Hope Medical Center
Sex: All
Age: 0+
Code: NCT04185935
Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.
for
Glaucoma, Open-Angle, Ocular Hypertension
Location: Cheyenne WY, Newport Beach CA, Petaluma CA, Houston TX,
Sponsor: Amneal Pharmaceuticals, LLC
Sex: All
Age: 18+
Code: NCT05401357
Phase3, Recruiting
Navigation and Parent Peer Support to Promote Access
for
Mental Disorder, Child, Mental Health, Family Health
Location: Cheyenne WY, Aurora CO, Pittsburgh PA
Sponsor: University of Colorado, Denver
Sex: All
Age: 1 - 70+
Code: NCT04029220
Recruiting
Small Cell Lung Cancer Community Engagement to Eliminate Research Discepancies
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases